These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26820720)

  • 21. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
    Choi C; Raisanen JM; Ganji SK; Zhang S; McNeil SS; An Z; Madan A; Hatanpaa KJ; Vemireddy V; Sheppard CA; Oliver D; Hulsey KM; Tiwari V; Mashimo T; Battiste J; Barnett S; Madden CJ; Patel TR; Pan E; Malloy CR; Mickey BE; Bachoo RM; Maher EA
    J Clin Oncol; 2016 Nov; 34(33):4030-4039. PubMed ID: 28248126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
    Andronesi OC; Loebel F; Bogner W; Marjańska M; Vander Heiden MG; Iafrate AJ; Dietrich J; Batchelor TT; Gerstner ER; Kaelin WG; Chi AS; Rosen BR; Cahill DP
    Clin Cancer Res; 2016 Apr; 22(7):1632-41. PubMed ID: 26534967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of 2-hydroxyglutarate in brain tumors by triple-refocusing MR spectroscopy at 3T in vivo.
    An Z; Ganji SK; Tiwari V; Pinho MC; Patel T; Barnett S; Pan E; Mickey BE; Maher EA; Choi C
    Magn Reson Med; 2017 Jul; 78(1):40-48. PubMed ID: 27454352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry.
    Longuespée R; Wefers AK; De Vita E; Miller AK; Reuss DE; Wick W; Herold-Mende C; Kriegsmann M; Schirmacher P; von Deimling A; Pusch S
    Acta Neuropathol Commun; 2018 Mar; 6(1):21. PubMed ID: 29499756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
    Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
    Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy.
    Natsumeda M; Motohashi K; Igarashi H; Nozawa T; Abe H; Tsukamoto Y; Ogura R; Okada M; Kobayashi T; Aoki H; Takahashi H; Kakita A; Okamoto K; Nakada T; Fujii Y
    Neurosurg Rev; 2018 Apr; 41(2):641-647. PubMed ID: 28956184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma.
    Iwahashi H; Nagashima H; Tanaka K; Uno T; Hashiguchi M; Maeyama M; Somiya Y; Komatsu M; Hirose T; Itoh T; Sasaki R; Sasayama T
    J Neurosurg; 2023 Aug; 139(2):355-362. PubMed ID: 36708540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
    Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM
    Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo Metabolic Profiles as Determined by
    Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
    Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T.
    Bisdas S; Chadzynski GL; Braun C; Schittenhelm J; Skardelly M; Hagberg GE; Ethofer T; Pohmann R; Shajan G; Engelmann J; Tabatabai G; Ziemann U; Ernemann U; Scheffler K
    J Magn Reson Imaging; 2016 Oct; 44(4):823-33. PubMed ID: 26970248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
    Zhou M; Zhou Y; Liao H; Rowland BC; Kong X; Arvold ND; Reardon DA; Wen PY; Lin AP; Huang RY
    Neuro Oncol; 2018 Aug; 20(9):1262-1271. PubMed ID: 29438510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 3D high-resolution imaging of 2-hydroxyglutarate in glioma patients using DRAG-EPSI at 3T in vivo.
    An Z; Tiwari V; Baxter J; Levy M; Hatanpaa KJ; Pan E; Maher EA; Patel TR; Mickey BE; Choi C
    Magn Reson Med; 2019 Feb; 81(2):795-802. PubMed ID: 30277274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
    Batsios G; Viswanath P; Subramani E; Najac C; Gillespie AM; Santos RD; Molloy AR; Pieper RO; Ronen SM
    Sci Rep; 2019 Jul; 9(1):10521. PubMed ID: 31324855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.
    Branzoli F; Di Stefano AL; Capelle L; Ottolenghi C; Valabrègue R; Deelchand DK; Bielle F; Villa C; Baussart B; Lehéricy S; Sanson M; Marjanska M
    Neuro Oncol; 2018 Jun; 20(7):907-916. PubMed ID: 29126125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study.
    Yu M; Ge Y; Wang Z; Zhang Y; Hou X; Chen H; Chen X; Ji N; Li X; Shen H
    J Neurooncol; 2024 Apr; 167(2):305-313. PubMed ID: 38424338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.
    Elkhaled A; Jalbert LE; Phillips JJ; Yoshihara HAI; Parvataneni R; Srinivasan R; Bourne G; Berger MS; Chang SM; Cha S; Nelson SJ
    Sci Transl Med; 2012 Jan; 4(116):116ra5. PubMed ID: 22238333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
    Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
    Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spectral fitting strategy to overcome the overlap between 2-hydroxyglutarate and lipid resonances at 2.25 ppm.
    Askari P; Dimitrov IE; Ganji SK; Tiwari V; Levy M; Patel TR; Pan E; Mickey BE; Malloy CR; Maher EA; Choi C
    Magn Reson Med; 2021 Oct; 86(4):1818-1828. PubMed ID: 33977579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
    Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
    Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic performance of edited 2HG MR spectroscopy of central glioma in the clinical environment.
    Juskanič D; Mištinová JP; Hollý S; Sekerešová M; Koleják K; Pátrovič L
    MAGMA; 2022 Feb; 35(1):45-52. PubMed ID: 34985589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.